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Objectives: This study examines changes in the expression of growth factors following thermal ablation
(TA) of selected colorectal cancer (CRC) liver metastases.
Methods: Using mice with established CRC liver metastases, two tumours in each animal were thermally
ablated. Liver and tumour tissues were collected at various time-points (days 0, 1, 2, 3, 5 and 7) following
TA treatment from the ablation site and from sites distant from ablated tumour. Changes in growth factor
expression (epidermal growth factor [EGF], vascular endothelial growth factor [VEGF], hepatocyte growth
factor [HGF] and transforming growth factor-b [TGF-b]) in comparison with baseline levels (non-ablated)
were assessed by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry.
Results: Baseline TGF-b and VEGF levels in the liver parenchyma of tumour-bearing mice were signifi-
cantly higher than levels in naive liver parenchyma. Levels of VEGF and HGF decreased after TA treatment
in all tissues. Levels of EGF decreased in ablated and distant tumour tissues, but displayed a tendency
to increase in liver tissue. Levels of TGF-b also decreased during the first 2 days following TA, but later
increased in liver and tumour tissues distant from the ablation site to a level that reached significance in
tumour tissue at day 7 (P < 0.001). Decreases in growth factor levels were also observed in animals that
underwent laparotomy without TA treatment, which indicates that these decreases were caused by the
experimental procedure.
Conclusions: Tumour induces upregulation of TGF-b and VEGF in liver parenchyma. Growth factors
decreased after TA, but this appears to be the result of the experimental procedure rather than the TA
itself. However, TA resulted in increased levels of TGF-b, which may contribute to tumour recurrence.
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Introduction
Colorectal cancer (CRC) is the most common solid organ cancer
across both genders and the third most common cause of cancer-
related deaths.1 More than 50% of patients with CRC will subse-
quently develop liver metastases (CRCLM), which represent the
leading cause of death in this population. Surgical resection is the
only potential curative option. The spatial distribution of
metastases, presence of extrahepatic disease, potential residual
liver volume and function, as well as the general health of the
patient, are the main factors that limit the surgical option to
approximately 10–25% of patients.2,3 Advances in systemic thera-
pies have progressively increased the potential for surgical inter-
vention by downstaging hepatic metastases in a small subset of
patients.4 Despite successful surgery, the majority of patients
experience disease recurrence, most frequently in the liver.
Residual micrometastases are thought to be the main aetiology for
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such recurrences. Several studies indicate that recurrence may be
significantly stimulated by the process of liver regeneration.5 The
mechanism of this stimulation remains unclear. However, a
number of growth factors (GFs) associated with liver regeneration
have been implicated as they have also been demonstrated to be
upregulated in aggressive tumours and to be able to promote
tumour growth in experimental in vitro and in vivo studies. These
GFs include transforming growth factor-b (TGF-b), epidermal
growth factor (EGF), vascular endothelial growth factor (VEGF)
and hepatocyte growth factor (HGF).5
Local thermal ablation (TA) was developed to increase the
therapeutic options for patients with liver metastases.6,7 This
involves the application of laser, radiofrequency or microwave
energy inside the tumour. The conversion of such energy to heat
leads to the destruction of the tumour by coagulative necrosis,
which extends to a rim of normal liver surrounding the tumour.
When applied as a minimally invasive technique, TA has a number
of potential advantages, including significantly lower morbidity
and minimal destruction of normal liver tissue, leading to lesser
regenerative response and the facility of repeated application.8,9
Experimental studies have also strongly suggested a positive effect
on host immune response following TA of tumours in which the
ablated tumour acts as a tumour vaccine.10,11 These studies have
also demonstrated the suppression of subsequent tumour chal-
lenge, as well as reduced systemic and intraperitoneal metastases.
Apart from the potential immunological responses, the smaller
volume of normal liver destroyed and the lower regenerative effort
may play a part in these outcomes. By contrast with experimental
studies, TA in clinical practice is associated with significant levels
of locally recurrent disease.6,12 The limitation of real-time imaging
of tumour destruction during TA may be partly responsible for
incomplete tumour destruction and local recurrence.13 However,
the effect of TA on the surrounding normal liver, its impact on
proinflammatory and proangiogenic cytokine release and their
effects on liver parenchyma and on any residual micrometastases
remain poorly defined. This study investigates changes in the local
expression (liver parenchyma and residual tumour) of the angio-
genic growth factors TGF-b, VEGF, HGF and EGF following TA of
selected tumours. We hypothesized that this scenario would reflect
changes occurring in the clinic after TA when residual microme-
tastases or tumour at the margins of an ablation site remain.
Materials and methods
Animals
Male CBA mice aged 6–8 weeks (Laboratory Animal Services,
University of Adelaide, Adelaide, SA, Australia) were maintained
in standard cages with access to irradiated food and water ad
libitum, and exposed to a 12:12-h light : dark cycle. All procedures
were implemented in accordance with the guidelines of the Austin
Health Animal Ethics Committee.
Experimental design
Three study groups were used: the first study aimed to establish
baseline GF expression in tumour and tumour-bearing liver
tissues and involved two groups of mice. The experimental group
was induced with metastatic tumour cells 21 days prior to tissue
collection. Controls consisted of a group of mice from the same
cohort that were not induced with tumour. The second study
investigated temporal changes in levels of GFs in liver and
metastases following TA (at days 0, 1, 2, 3, 5 and 7) compared with
baseline levels (day 21 post-tumour induction and day 0 post-TA
treatment). The third study was undertaken in response to unex-
pected findings in the second study and investigated GF changes
in groups of animals that were sham-ablated in order to establish
whether a number of results reflected experimental procedures
rather than the TA.
Experimental model of CRC liver metastases
The primary cell line MoCR was derived from a dimethyl hydra-
zine (DMH)-induced primary colon carcinoma in the CBA
mouse and maintained in vivo by serial passage in the flanks of
CBA mice.14 Liver metastases were induced by an intrasplenic
injection of 5 ¥ 104 tumour cells prior to splenectomy, as reported
previously.14 In this model, liver metastases are fully established by
21 days following tumour induction. For passage and experimen-
tation, tumours grown subcutaneously were teased and washed in
phosphate-buffered saline (PBS) to make a single-cell suspension.
Thermal ablation treatment
Thermal ablation of liver tumours was performed using a diode
laser with a 400-mm bare tip optical quartz fibre (D-6100-BF;
Dornier MedTech Laser GmbH, Wessling, Germany), applying
40 J of power per tumour (20 s at 2 Watt). The treatment param-
eters were chosen based on our previous extensive studies exam-
ining the nature and extent of injury, including temperature
profiles.15–18 Average tissue temperatures reach 65 °C adjacent to
the fibre site without causing tissue charring. Higher power set-
tings in this animal model generally produce charring. The setting
used produces incomplete tumour necrosis extending to the
tumour margins. Animals were divided into groups (n = 6) and
were anaesthetized. A bilateral sub-costal incision was performed
to expose the liver. Similarly located intraparenchymal tumours,
7 mm in diameter, were chosen for sub-total laser ablation. A
marking tissue dye (Davidson Tissue Marking System; Bradley
Products, Grale Scientific Pty Ltd, Melbourne, Vic, Australia) was
applied to each treated tumour for identification. For the day 0
time-point, the whole liver was removed immediately after TA and
samples collected. For other time-points, the abdomen was closed
with sutures and the animals were allowed to recover until they
were killed at specific time-points (days 1, 2, 3, 5 and 7) following
TA treatment. In the sham ablation study, the probe was inserted
into the selected tumour, but not activated. Animals were killed at
time-points matched to those used in the TA groups.
Tissue sample collection
At each endpoint after TA treatment, mice were anaesthetized and
the liver excised. The two ablated or sham-treated tumours were
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identified and immediately dissected from the liver, together with
surrounding liver tissue. Each tumour was cut into halves with a
sharp blade. One half was fixed in 10% formalin; the other half,
cleared from liver tissue, was snap-frozen in liquid nitrogen.
Samples of liver tissue and untreated tumours distant from the
ablation site were also collected from sites as shown in Fig. 1 and
processed as above. All frozen specimens were stored at -80 °C for
future lysate preparation. Formalin-fixed specimens were pro-
cessed for immunohistochemistry.
Immunohistochemistry
Formalin-fixed, paraffin-embedded, 4-mm thick sections of the
tissues were deparaffinized and rehydrated using standard tech-
niques. Endogenous peroxidases were blocked by incubation in
3% peroxide in methanol for 10 min. Antigen retrieval was per-
formed by treating sections with ethylene diamine tetra-acetic
acid (EDTA) pH 8 for 20 min at 99 °C. For HGF staining, enzy-
matic digestion using 0.1% trypsin solution at 37 °C for 1 h was
used for antigen retrieval. Normal goat serum (20%) was used to
block non-specific binding. Commercially available rabbit
primary antibodies raised against the mouse GFs (or cross-
reactive to them) were used for staining (EGF: E2635 [Sigma-
Aldrich Pty Ltd, Castle Hill, NSW, Australia] at 1 : 1500 dilution;
HGF: sc7949 [Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA] at 20 mg/ml; TGF-b: sc7892 [Santa Cruz Biotechnology,
Inc.] at 2 mg/ml; VEGF: Ab-4 PC315 [EMD Biosciences, San
Diego, CA, USA] at 1.5 mg/ml). For negative controls, sections
were incubated with non-immune rabbit immunoglobulin G
(IgG) only (DakoCytomation Norden A/S, Glostrup, Denmark) at
the same concentration as the primary antibody. Sections were
incubated with primary antibodies overnight at 4 °C. A polymer-
based detection kit containing goat anti-rabbit immunoglobulins
(IgG) complexed with horseradish peroxidase (HRP) (EnVision
Plus™; DakoCytomation Pty Ltd, Botany, NSW, Australia) was
then used. Each incubation step was followed by two 5-min
washes with PBS plus 0.05% Tween 20. The presence of GFs was
visualized using diaminobenzidine (DAB) as a substrate.
Preparation of protein extracts from liver or
tumour tissues
Collected tissues that were snap-frozen in liquid nitrogen as pre-
viously described were used for protein preparations. The tissues
were weighed into microcentrifuge tubes and kept on ice. Cold
lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM EDTA,
10 mM Na4P2O7, 10 mM NaF, 2 mM Na3VO4, 0.5 mM PMSF,
20 mM leupeptine, 10 mg/ml aprotinine and 1% triton X-100) was
added to each tissue at a ratio of 5 volumes/mg tissue weight. The
tissues were homogenized using an Ultra Turrax T25 homog-
enizer (John Morris Scientific Pty Ltd, Sydney, NSW, Australia) in
three 10-s bursts while the sample was kept on ice. The homoge-
nates were then sonicated in three 10-s bursts using a Branson
Sonifier 250 (Branson Ultrasonics Corp., Danbury, CT, USA) at a
constant output of 30 Hz while the sample was kept on ice. The
sonicates were centrifuged at 17 000 g at 4 °C for 15 min and the
supernatant (lysate) was collected, aliquoted and kept frozen at
-80 °C until used.
Enzyme linked immunosorbent assay
An enzyme-linked immunosorbent assay (ELISA) was used to
determine tissue levels of TGF-b1, VEGF, HGF and EGF. Growth
factor concentrations in tissue extracts were determined with a
sandwich ELISA using commercially available kits (mouse
DuoSets®: EGF, DY2028; HGF, DY2207; VEGF, DY493; TGF-b1,
DY1679; R&D Systems, Inc., Minneapolis, MN, USA). The assay
was performed according to the manufacturer’s instructions with
minor modifications. In brief, the capture antibody was suitably
diluted in PBS and then used to coat 96-well microplates (Nunc
Immuno Plate Maxisorb; In Vitro Technologies Pty Ltd, Noble
Park, Vic, Australia) at 50 ml per well. The plates were incubated
overnight at 4 °C. Free binding spaces were blocked with the
appropriate reagent diluent and test samples and standards were
applied at suitable concentrations. Samples of TGF-b were acti-
vated using 2.5 N acetic acid/10 M and neutralized by 2.7 N
NaOH/1.0 M HEPES as recommended by the kit manufacturer
before being applied to the ELISA plate. After a 2-h incubation,
biotinylated detection antibody was added, followed by
Streptavidin-HRP. The plate was washed before each successive
step with 0.05% Tween 20 in PBS. Substrate (H2O2 and tetram-
ethylbenzidine, DY994; R&D Systems, Inc.) was added and devel-
oped for 20 min at room temperature. The colour development
Figure 1 Schematic representation of thermal ablation (TA) treat-
ment and areas of tissue collection for growth factor analysis. Two
tumours were selected and ablation was performed using a 400-mm
bare tip optical quartz fibre diode laser, applying 40 J of power per
tumour (20 s at 2 Watt). In the sham-ablated groups, the probe was
inserted into two selected tumours, but was not activated. Treated
tumours were marked with tissue dye for future identification.
Tissues from treated tumours, distant tumours and distant liver
parenchyma were collected from the areas shown and used for
immunochemistry and lysate preparations
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was terminated by the addition of 25 ml of stop solution (2 N
H2SO4). The optical density was determined immediately using a
microplate reader (Benchmark Plus Microplate Spectrophotom-
eter System; Bio-Rad Laboratories, Inc., Hercules, CA, USA) set at
dual wavelengths of 450 nm and 540 nm. The 540-nm reading was
subtracted from the 450-nm reading. Using a computer-generated
four-parameter logistic (4-PL) curve fit from the standard absor-
bance values and the corresponding concentrations, the unknown
sample concentrations were directly calculated by the spectropho-
tometer software.
Statistical analysis
All data are expressed as the mean  standard error of the mean
unless otherwise stated. Data were tested for normality. Pairwise
comparisons of group means for parametric data were performed
using either Student’s t-test or analysis of variance (anova) with
post-hoc analysis (Scheffé for groups with equal variances and the
Games–Howell method for groups with unequal variances, as
appropriate). All statistical analyses were performed using spss
Version 16.0 (SPSS, Inc., Chicago, IL, USA).P-values of <0.05 were
considered statistically significant.
Results
Effect of liver metastases on the expression of
angiogenic growth factors
The expression of angiogenic GFs in the tumour and liver was
evaluated by ELISA at 21 days after tumour induction when
CRCLM are fully established. Animals not induced with tumour
were used as controls to assess baseline expression. Liver paren-
chyma of tumour-bearing animals expressed higher levels of
TGF-b, VEGF and HGF compared with normal liver. Significant
increases were found in the expression of TGF-b (62.4 
19.2 pg/mg vs. 8.5  0.7 pg/mg; P = 0.043) and VEGF (1938 
136 pg/mg vs. 453  243 pg/mg; P < 0.001), but the increase in
HGF did not reach significance (Fig. 2). There was no significant
difference in EGF expression between the two groups.
In animals with CRCLM, expression of VEGF, HGF and EGF
was lower in tumour tissues compared with surrounding liver
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Figure 2 Baseline growth factor (GF) expression in tumour-bearing mice. Growth factor levels in tumour tissue ( ; day 21 post-tumour
induction, n = 5), liver tissue of tumour-bearing mice ( ; day 21 post-tumour induction, n = 5) and liver tissue of control mice ( ; non-induced
with tumour, n = 4) was determined by enzyme-linked immunosorbent assay (ELISA) using specific GF ELISA kits supplied with recombinant
GF protein for the standard curve. Levels of transforming GF-b (TGF-b) and vascular endothelial GF (VEGF) are significantly higher in
tumour-bearing liver tissue compared with controls (P < 0.0001 for both). Levels of hepatocyte GF (HGF) and epidermal GF (EGF) in
tumour-bearing mice did not differ significantly from those in control mice (P = 0.443 and P = 0.305, respectively)
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parenchyma (Fig. 2), but there was no difference in expression of
TGF-b. These differences in the expression of GFs between
tumour tissue and the surrounding liver parenchyma were also
seen with immunohistochemistry (Fig. 3A–D, row 1), in which
TGF-b stained strongly in both tumour and liver parenchyma. By
contrast, HGF and, in particular, VEGF displayed strong staining
in liver parenchyma while exhibiting only weak expression in
tumour tissue. Expression of VEGF in tumour tissue was hetero-
geneous, with groups of tumour cells expressing VEGF and others
demonstrating none (Fig. 3B, row 1). The growth factors TGF-b,
VEGF and EGF were expressed in the cytoplasm of both tumour
cells and hepatocytes, whereas HGF was also strongly localized
within the nuclear region of some hepatocytes and tumour cells
(Fig. 3C, row 1).
Temporal changes in histopathology and growth
factor immunostaining in liver and tumour tissues
following thermal ablation
Two liver metastases underwent TA in each animal with CRCLM.
Tissues were collected at days 0, 1, 2, 3, 5 and 7 after ablation.
Immediately following ablation, tumour cells within the ablated
region appeared disorganized histologically, with loss of cell
Figure 3 Haematoxylin and eosin (H&E) and immunostaining of control and thermally ablated tissues. Original magnification ¥400. Row 1
(A–D): control tumour tissues stained for transforming growth factor-b (TGF-b), vascular endothelial growth factor (VEGF), hepatocyte growth
factor (HGF) and epidermal growth factor (EGF), respectively. Row 2: H&E staining of ablated tumour section (A) immediately after ablation,
(B) magnified inset of (A) showing inflammatory cell infiltration, (C) at day 1 after ablation, and (D) at day 7 after ablation. Arrows in (D) indicate
prominent fibrotic deposition. Row 3: (A, C) ablated and distant tumour sections, respectively, stained for TGF-b; (B) and (D) are magnified
insets of (A) and (C), respectively, showing inflammatory cell infiltration with positive staining. Row 4: (A, C) ablated and distant tumour
sections, respectively, stained for EGF; (B) and (D) are magnified insets of (A) and (C), respectively, showing inflammatory cell infiltration with
positive staining. L, liver parenchyma, T, tumour tissue. Small arrows indicate leukocyte infiltration
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contact on histology (Fig. 3A, row 2). This was accompanied by a
significant influx of leukocytes, as seen in the magnified inset
(Fig. 3B, row 2). At day 1, the ablative changes had progressed to
involve the adjacent liver parenchyma, with resultant alterations
in cellular morphology and loss of nuclei (Fig. 3C, row 2). By day
7, the ablated tumours exhibited substantial necrosis of tumour
cells extending to the tumour margins, tissue cavitation and
prominent fibrosis in the treated region (Fig. 3D, row 2). This is
consistent with findings in our previous studies, as we will
describe in the Discussion. Immunohistochemical staining of
ablated tumour tissues reflected the tissue injury pattern observed
using haematoxylin and eosin (H&E) staining. The specific stain-
ing appeared to diminish at each successive time-point compared
with that in untreated controls, as demonstrated in Fig. 3(A)
(rows 3 and 4) in treated tissues stained for TGF-b and EGF,
respectively, at day 2. Similar reductions in GF staining after treat-
ment occurred in the distant untreated tumour tissues (Fig. 3C,
rows 3 and 4). As the H&E staining shows, infiltrating cells are
present in the immunostained sections. A proportion of the infil-
trating cells stained strongly positive for TGF-b and EGF, particu-
larly in ablated tumours, in which they are more prominent at the
injury front (Fig. 3B, rows 3 and 4), although they are also appar-
ent in distant untreated tumours (Fig. 3D, rows 3 and 4). In addi-
tion, the treated tissues generally displayed higher background
non-specific staining compared with untreated controls or tissues
distant from the ablation site.
Temporal changes in the expression of angiogenic
growth factors after thermal ablation
Expression of TGF-b, VEGF, HGF and EGF was assessed by
ELISA. The temporal changes in GF expression were compared
with their respective baseline values (day 0). Baseline values for
each GF did not differ significantly from those in the untreated
tumour-bearing control group (Figs 2, 4).
Following TA, all four GF levels decreased in the ablated
tumour tissues at all time-points. At particular time-points, this
decrease differed significantly from baseline (Fig. 4). With the
exception of TGF-b, a similar decreasing trend in GF levels was
also seen in tumour tissues distant from the ablated sites. As in the
ablated tumours, this decrease resulted in levels significantly lower
than baseline values at certain time-points (Fig. 4). A significant
reduction in the expression of TGF-b was also seen in distant
untreated tumours on days 1 (P < 0.02) and 2 (P < 0.03) compared
with baseline levels. This was followed by a rapid increase in
expression at day 5, which resulted in a statistically significant
difference compared with baseline by day 7 (P < 0.001) (Fig. 4A).
Growth factor changes also occurred within the liver tissues
following tumour ablation. Levels of TGF-b, VEGF and HGF sig-
nificantly decreased after treatment. The time-point at which
expression fell to a level significantly lower than baseline differed
for each factor. Levels of TGF-b decreased significantly at days 1
and 2 following treatment and then increased above baseline levels
at days 5 and 7 in a pattern similar to that seen in distant tumour
tissues (Fig. 4A). The increase, however, did not reach signifi-
cance. Expression of VEGF was significantly lower at all time-
points from day 1 after treatment onwards (P < 0.001) (Fig. 4B).
Expression of HGF showed a decreasing trend from day 1 post-
treatment and became significantly lower than at baseline at days
5 and 7 (Fig. 4C). Levels of EGF, unlike those of the other GFs,
increased in the liver tissue; however, this increase was not found
to be statistically significant at early time-points after treatment.
Expression of EGF then returned to baseline levels by day 7
(Fig. 4D).
Temporal changes in the expression of angiogenic
GFs after sham ablation
Published studies report increases in GF levels following tumour
resection.5 We expected to find some increase in GF levels follow-
ing TA in this study, but, on the contrary, with the exception of
TGF-b, GF levels decreased after treatment. To investigate whether
any of these changes were caused by the experimental procedures
(laparotomy), groups of mice were treated as shams. These mice
underwent laparotomy in which the liver was exposed and the
laser probe was inserted into two tumours but was not activated
(sham ablation). Tissues were collected at time-points equivalent
to those used in the TA study. Changes in levels of GF expression
in these tissues were assessed and were found to be similar to those
seen in the tissues in the TA treatment study, with one exception:
levels of TGF-b remained below baseline levels at all time-points
tested (results not shown).
Discussion
Because of its low morbidity rates, limited hepatic parenchymal
damage and applicability to a wider cross-section of the target
population, local TA has the potential to be used as an alternative
to surgery. It is available for patients who are not suitable for
surgical intervention as a result of the spatial distribution of the
tumour, limited hepatic reserve or lack of general fitness. In addi-
tion, there is a sound theoretical basis and accumulating experi-
mental evidence to indicate that TA would reduce the incidence of
recurrent disease. The major disadvantage of using TA in the clinic
is that patients who undergo this treatment are subject to a high
rate of local recurrence in the liver, mainly as a result of incom-
plete tumour destruction stemming from problems with tumour
imaging in the percutaneous procedure. In a study by Elias et al.,
in which radiofrequency ablation (RFA) was performed with lap-
arotomy, survival rates were equivalent to those in anatomical or
wedge resections.19
We have extensive experience in both clinical20 and experimen-
tal application of laser TA for CRCLM. We have previously char-
acterized the effects of TA at the cellular level on temperature
profiles,15–18 temporal injury progression,21,22 tumour microvascu-
lature,16,18 blood flow occlusion23 and in combination with
thermal sensitizers.24 We have demonstrated no additional
tumour stimulation by TA.25 The current study continues our
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Figure 4 Temporal changes in growth factor (GF) expression in liver and tumour tissues following thermal ablation. Six groups of tumour-
induced mice (for days 0, 1, 2 and 3 [n = 6] and days 5 and 7 [n = 4]) were used. Two selected tumours were ablated and tissues collected
post-treatment as shown in Fig. 1 at the time-points indicated. Growth factor levels in tissue lysates were determined by enzyme-linked
immunosorbent assay (ELISA). , ablated tumour; , liver tissue; , distant tumour. , represents baseline expression of GF in untreated
tumour-bearing liver tissue. (A) Temporal changes in transforming GF-b (TGF-b) expression. Significantly lower levels of expression were
observed at days 1 and 2 in the ablated tumour tissues (P = 0.022 and P = 0.029, respectively) compared with at baseline. Significantly higher
levels of expression were seen in the distant tumour tissue of ablated animals at day 7 (P < 0.001) compared with baseline. (B) Temporal
changes in vascular endothelial GF (VEGF) expression. Significant decreases in expression from baseline were observed at all time-points
after day 1 in liver tissues (P < 0.001) and at day 2 in tumour tissues (P = 0.038 for ablated tumour and P = 0.003 for distant tumour). (C)
Temporal changes in hepatocyte GF (HGF) expression. Significant decreases in expression from baseline were observed at days 5 (P =
0.049) and 7 (P = 0.046) in liver tissue and at all time-points except day 7 in ablated tumour tissues (P = 0.008 at day 1, P = 0.007 at day
2, P = 0.003 at day 3, P = 0.005 at day 5, P = 0.105 at day 7). Levels of HGF in distant tumour tissues differed significantly from baseline
only at day 5 (P = 0.008). (D) Temporal changes in epidermal GF (EGF) expression. In the TA-treated animals significant decreases in
expression from baseline were observed in ablated tumour tissues at days 5 and 7 (P = 0.031 and P = 0.041, respectively)
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published work characterizing the various aspects of TA and, in
particular, focuses on the effect of TA on angiogenic GFs.
In establishing the baseline expression of the four GFs in liver
and tumour tissue, we have demonstrated that VEGF, HGF and
EGF expression in the surrounding liver parenchyma is higher
than that found within the tumour. More importantly, we found
that liver parenchyma in tumour-bearing mice expresses signifi-
cantly increased levels of TGF-b and VEGF in comparison with
normal liver. In another study, Meredith et al. demonstrated sig-
nificant increases in mRNA levels of HGF and basic fibroblast GF
(bFGF) between tumour-bearing liver and normal liver in a dif-
ferent CRCLM model.26 In our study, HGF expression demon-
strated an increasing trend, but this did not reach statistical
significance. These findings suggest that the presence of tumour
influences the liver parenchyma, leading to increased expression
of proangiogenic GFs which may support and sustain tumour
growth. As this was an unexpected finding further studies using
more appropriate controls (carrier-injected and splenectomized
mice) are required to verify these findings and to investigate addi-
tional changes induced by the presence of tumour.
Following TA treatment, tumour cells show progressive injury
and death. By day 7 no normal tumour structure can be seen,
although dissociated live tumour cells remain at the tumour
margin. Limited injury at this stage has also spread into the adja-
cent liver parenchyma. These effects on the tumour seen in this
study are in agreement with our earlier findings.17 All GFs dis-
played progressively decreasing levels within the ablated tumours
following treatment. This is as expected, given that the tissue is
becoming progressively necrotic and the proteins denatured.
However, with the exception of TGF-b, a progressive decrease in
GF expression after TA was also seen in tumours distant from the
ablation site, which was unlikely to be a result of local injury.
Additionally, similar GF decreases were seen in the tumours in the
control groups. Similarly, expression of HGF and VEGF progres-
sively decreased in the liver parenchyma in both the ablated and
control groups, whereas that of EGF did not change significantly
in the liver parenchyma in either group. These findings strongly
suggest that, with the exception of TGF-b, the GF changes reflect
a systemic effect in the animal in response to laparotomy and
manipulation. Meredith et al.26 reported decreases in liver bFGF
and HGF mRNA levels at days 2 and 3, respectively, following TA
in a mouse model of a single implanted tumour in the liver. The
decrease was attributed to the complete eradication of the single
tumour and therefore the removal of the stimulus. This explana-
tion cannot account for our findings as the decrease in GFs in our
study occurred after the ablation of two specific tumours in the
presence of multiple distant untreated tumours. In addition, we
found similar decreases in GFs in the sham-ablated animals, in
which no tumour destruction occurred. In light of this, it is
important to note that no sham group was included in the study
reported by Meredith et al.26 In another study, Isbert et al.27 com-
pared the effects of TA or resection on HGF mRNA levels using an
implanted CRC rat tumour model. In this study,27 two tumours
were implanted, but only one was ablated, resembling the design
of our experiment. Isbert et al.27 reported that HGF mRNA levels
at 48 h were significantly lower in distant tumours in animals
undergoing TA compared with those undergoing resection. By
contrast, no difference emerged between TA-treated animals and
sham-ablated controls at this time-point, which is in agreement
with our findings. Isbert et al.27 did not present baseline GF levels
(day 0) that may also have shown a temporal decrease, as in our
study. In agreement with our study, these two studies26,27 reported
decreased expression of particular GFs following TA, with an
increase in HGF common to all three studies. We demonstrated a
similar decrease in GF expression in the sham-ablated controls,
suggesting that the decrease most likely reflects a general effect of
laparotomy rather than TA. One possible explanation for this
reduction is that the major injury caused by laparotomy mobilized
local tissue stores of GFs towards the site of the injury (dissected
peritoneal muscles), thus leading to local depletion in organs such
as the liver. If this hypothesis is correct, a concomitant systemic GF
increase would be expected. A recent human study by Evrard et al.
reported systemic increases in HGF and VEGF following laparo-
tomy and RFA treatment,28 thus supporting our hypothesis.
However, further studies are necessary to unequivocally demon-
strate that laparotomy reduces the GFs in the liver and possibly in
other organs. By contrast with the findings that laparotomy and
local tumour ablation result in a local decrease in GF expression,
laparotomy and liver resection resulted in significant local
increases in several GFs.26,27,29 This difference may be a measure of
the extent of liver injury in the two procedures. Liver resection
requires the prompt replacement of liver mass by regeneration as
liver function is of the utmost importance for survival. By con-
trast, TA causes minor localized liver injury, which does not lead
to significant regeneration, and the wound healing of the laparo-
tomy may represent a more urgent demand on the animal’s
healing resources.
The exception to these findings concerns the expression of
TGF-b in the aftermath of TA. After an initial reduction at days 1
and 2, there was a significant increase above baseline levels in the
treated groups. This is likely to represent a specific response to TA
because it was not seen in the sham-ablated groups. This finding
may have clinical significance as high serum levels of this GF
following liver tumour resection were shown by Tsushima et al. to
be a negative predictor for survival in cancer patients.30 Increases
in TGF-b levels were also reported by Ohno et al. following
tumour microwave coagulation therapy.31 Additionally, an
increase in connective tissue GF (CTGF) expression, a down-
stream effector of the TGF-b signalling pathway, was seen in
distant tumours after TA by Isbert et al.27 Over-expression of
CTGF in liver has been associated with hepatic fibrosis.32
Although we did not investigate changes in CTGF in our study, we
did observe what appears to be fibrotic tissue accumulation in the
TA-treated areas. TGF-b is a multifunctional GF and plays impor-
tant roles in injury and healing, liver regeneration, tumour growth
and metastasis.5,33–35 The upregulation of TGF-b may well repre-
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sent a healing response to the injury caused by TA. However, this
upregulation may also have an impact on the growth of residual
dormant micrometastases or tumour remnant at a site of incom-
plete TA and thus contribute to disease recurrence.30 The large
infiltration of leukocytes seen in the ablated area and in the distant
tumours following TA may contribute to tumour inhibition by the
induction of anti-tumour immune responses.11,36 We have evi-
dence of macrophage and T cell accumulation and interferon-g
(IFN-g) upregulation within the ablated sites and in distant
tumours after TA treatment (present authors, unpublished results,
2010). However, a proportion of infiltrating cells stained strongly
for GFs, particularly for TGF-b and EGF, within the ablated
viable/necrotic tissue interface, which supports our earlier obser-
vation.22 These GF-positive infiltrating cells may contribute to
tumour regrowth. Thus, tumour recurrence may depend on the
net balance between proinflammatory and proangiogenic factors
in the residual tumour microenvironment.
In conclusion, whereas tumour removal by liver resection
results in increased expression of GFs shown to play key roles in
the stimulation of tumour growth and recurrence, TA treatment
of tumours results in the local reduction of GF expression. The
only exception to this finding concerned expression of TGF-b,
which significantly increased after TA. The observed reduction in
GF expression is in agreement with two other published studies on
TA treatment.26,27 Our study, however, also shows similar reduc-
tions in GFs in the control groups, prompting us to suggest that
the observed changes are caused by laparotomy rather than TA
treatment. The two other studies26,27 did not include sufficient
controls to indicate the same conclusion.
Our study demonstrated significant increases in local TGF-b
expression in response to TA. As this GF is closely associated with
tumour progression and poor prognosis, we believe further
studies should explore the inhibition of this GF in combination
with TA for more effective anti-tumour treatment.
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